DUAL THERAPY FOR ALZHEIMER'S DISEASE
Several research groups were searching for the role of Porphyromonas gingivalis (P. gingivalis) bacteria and Alzheimer's disease (AD). P. gingivalis bacteria consider as one of the main causes of chronic periodontitis in human.
Recently, researchers have found that proteins produced by P. gingivalis which called "Gingipain" are present in higher concentrations in the brains of people with Alzheimer's disease (AD). Furthermore, P. gingivalis DNA could be isolated from the cerebrospinal fluid (CSF) of AD patients.
In experiments on mice, the researchers found that mice infected by mouth with P. gingivalis later showed signs similar to those found in humans with early-stage dementia. They found that a reduce the bacterial infection able to stop brain deterioration.
Furthermore, Amyloid beta (Aβ ) is crucially involved in Alzheimer's disease as the main component of the amyloid plaques found in the brains of Alzheimer. According to the 'amyloid cascade' hypothesis, the aggregation of Aβ initiates a sequence of events leading to the formation of tangles, neurodegeneration, and on to the main symptom of dementia. Therefore, Aβ considers as a potential target for the treatment of AD.
MeSCue-Janusys own novel peptides inhibitors for Gingipain and Aβ which consider as promising drug candidates for the dual therapy of AD.
We are going to use both therapeutic potentials of our novel peptides to develop a dual therapy for prevention and treatment of AD.